vimarsana.com
Home
Live Updates
CTB001, Bioheng auto CAR - T Product, received Orphan Drug D
CTB001, Bioheng auto CAR - T Product, received Orphan Drug D
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA
/PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell...
Related Keywords
China ,
Decheng ,
Guangdong ,
Japan ,
United States ,
Nanjing ,
Jiangsu ,
,
National Intellectual Property Management Enterprise ,
Unicorn Enterprises ,
Drug Administration ,
National Science ,
Immunotherapy Excellence Center ,
Innovation Talents Program Of Jiangsu Province ,
Office Of Orphan Products Development ,
Bioheng Biotech Co Ltd ,
Orphan Drug Designation ,
Bioheng Explored ,
Prescription Drug User Fee Act ,
Orphan Products Development ,
Hillhouse Venture Capital ,
Decheng Capital ,
Octagon Capital ,
Jiangsu Province ,
Nanjing High Level Entrepreneurial Talent Plan ,
Nanjing Expert Studio ,
Nanjing Bioheng Biotech Co ,
Td ,